Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma

Read full text Summarise with VIRAT
Authors: Andrea Kühnl, Amy A. Kirkwood, Michael Northend, Rajesh Alajangi, Ben Uttenthal, Jane Elizabeth Norman, Hwai Jing Hiew, Frances Seymour, Bernard D. Maybury, Wendy Osborne, Francesca Emily Sillito, Ahmed Abdulgawad
+18 more Ceri H. Jones, Alison Delaney, William M. Townsend, Aikaterini Panopoulou, John G. Gribben, Edward J. Bataillard, Amrith Mathew, Nicolás Martínez‐Calle, Lavanya Gajendran, Andrew John Davies, Nikesh Dhiraj Chavda, Emil Arjun Kumar, Robin Sanderson, Sachin Kamat, George S. Petrides, Claire Roddie, Tobias Menne, Sridhar Chaganti
Cited by: 0
References: 27

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ABSTRACT: Patients with large B-cell lymphoma who progress after second-line (2L) chimeric antigen receptor T cell (CAR T) therapy have an increasing number of post-CAR T treatment options available and should be considered for timely intervention if at high risk of CAR T failure. In this national cohort of 302 patients receiving 2L axicabtagene ciloleucel (axi-cel), we assessed the use of early fluorodeoxyglucose positron emission tomography (PET) response to guide post-CAR T management. A total of 245 patients with treatment response at 1 month were grouped according to depth of response by Deauville score (DS): complete metabolic response or focal residual activity in the bridging radiotherapy field (DS1-3/DS4RT), partial response (PR) DS4, and PR DS5. DS response categories were significantly associated with risk of progression, progression-free survival, and overall survival. Patients with DS4 and DS5 response had a 50% and 73% risk of progression by month 6, respectively, compared with 25% for DS1-3/DS4RT (DS4: hazard ratio [HR], 3.07 [95% CI: 1.85-5.07] and DS5: HR, 5.20 [95% CI: 2.95-9.16]; P< .0001), which was independently significant in multivariable analyses. In a risk model using DS categories and preinfusion lactate dehydrogenase levels ≥2 upper limit of normal, we identified a high-risk group with significant risk of early failure (HR, 5.21 [95% CI: 3.27-8.29]; P< .001). Our results demonstrate the prognostic value of early PET response in patients treated with 2L axi-cel, independent of preinfusion risk factors. Responding high-risk patients had ≥70% risk of progression by month 6 and should be strongly considered for early post-CAR T therapies.

Fields of Study & Subjects

CAR-T cell therapy research Lymphoma Diagnosis and Treatment Cutaneous lymphoproliferative disorders research

Publication details

Journal / source
Blood Advances
Volume
10
Issue
11
Pages
3777–3786
Publication date
27 March 2026
Language
EN